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Abstract
Background: Previous work has demonstrated the potential for peripheral blood (PB) gene expression profiling for the
detection of disease or environmental exposures.
Methods and Findings: We have sought to determine the impact of several variables on the PB gene expression profile of
an environmental exposure, ionizing radiation, and to determine the specificity of the PB signature of radiation versus other
genotoxic stresses. Neither genotype differences nor the time of PB sampling caused any lessening of the accuracy of PB
signatures to predict radiation exposure, but sex difference did influence the accuracy of the prediction of radiation
exposure at the lowest level (50 cGy). A PB signature of sepsis was also generated and both the PB signature of radiation
and the PB signature of sepsis were found to be 100% specific at distinguishing irradiated from septic animals. We also
identified human PB signatures of radiation exposure and chemotherapy treatment which distinguished irradiated patients
and chemotherapy-treated individuals within a heterogeneous population with accuracies of 90% and 81%, respectively.
Conclusions: We conclude that PB gene expression profiles can be identified in mice and humans that are accurate in
predicting medical conditions, are specific to each condition and remain highly accurate over time.
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Introduction
Invasive procedures are often required for accurate screening
and diagnosis of common medical conditions [1]. Examination of
the peripheral blood often suffices to establish certain diagnoses,
such as chronic lymphocytic leukemia [2], which afflicts the
circulating lymphocyte directly. Measurement of total white blood
cell counts and the WBC differential (e.g. neutrophils, lympho-
cytes, monocytes) is routinely performed in medical practice and
can facilitate many diagnoses (e.g. bacterial or viral infection).
Recently, it has been suggested that gene expression profiling of
peripheral blood cells, particularly lymphocytes, can serve as
sensitive tool to assess for the presence of certain diseases, such as
systemic lupus erythematosus, rheumatoid arthritis, neurologic
disease, viral and bacterial infections, breast cancer, atherosclerosis
and environmental exposures, including tobacco smoke [3–11].
Results from these studies suggest that patterns of gene expression
within circulating PB cells can distinguish individuals afflicted by
these conditions from those who are not [3–11]. It has therefore
been suggested that PB gene expression profiling has potential
utility in the screening for diseases and environmental exposures.
However, any consideration of applying PB gene expression
profiles for the detection of disease or environmental exposures
requires a determination of the impact of PB cellular composition,
time, gender, and genotype on PB gene expression [10–13].
Additionally, it is unclear whether PB gene expression profiles that
have been associated with various medical conditions are specific
for that phenotype, or rather reflect a generalized response to
genotoxic stress. Examination of the specificity of PB gene
expression profiles in response to different stimuli and the
durability of these signatures over time will be critical to allow
the translation of this strategy into clinical practice.
Ionizing radiation represents a particularly important environ-
mental hazard, which, at lowest dose exposures, causes little acute
health effects [14] and, at higher dose exposures, can cause acute
radiation syndrome and death [15–17]. Numerous studies have
been performed to attempt to understand the biologic effects of
ionizing radiation in humans and specific mutations in p53 and
HPRT have been identified in somatic cells from survivors of the
Hiroshima and Nagasaki atomic bombings [18–21]. Gene
expression analyses have also been performed on human tumor
cells, cell lines, and peripheral blood from small numbers of
irradiated patients in order to identify specific genes that are
involved in the response to radiation injury [22–26]. Recently,
public health focus has centered on the development of capabilities
to accurately screen large numbers of people for radiation
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materials by terrorists to produce ‘‘dirty bombs’’ or ‘‘improvised
nuclear devices’’ [15–17]. We have introduced a method of
screening humans for environmental exposure by showing that
patterns of gene expression, or metagenes, can be identified in PB
cells that accurately distinguish between irradiated and non-
irradiated individuals [27]. As importantly, metagenes could be
identified in the PB that distinguished different levels of exposure
from each other with an accuracy of 96% [27].
In this study, we sought to evaluate the specificity of these PB
signatures, as well as to determine the influence of genetic
variation and time on the performance of the signature. We
conclude that this approach represents a viable strategy for
identifying environmental exposures and could be employed for
screening populations of affected individuals.
Methods
Murine irradiation study
Ten to 11 week old male and female C57Bl6 and female
BALB/c mice (Jackson Laboratory, Bar Harbor, ME) were housed
at the Duke Cancer Center Isolation Facility under regulations
approved by the Duke University Animal Care and Use
Committee. Between 5–10 mice/group were given total body
irradiation (TBI) with a Cs137 source at an average of 660cGy/
min at doses of 50, 200, or 1000cGy as previously described [27].
Six hours, 24 hours, or 7 days post-TBI, approximately 500 ul
peripheral blood was collected by retro-orbital bleed from both
irradiated and control mice. PB mononuclear cells (PB MNCs)
were isolated for total RNA extractions. Total RNA was extracted
with Qiagen RNAeasy Mini Kits as previously described [27].
RNA quality was assayed using an Agilent Bioanalyzer 2100
(Agilent Technologies, Inc., Palo Alto, CA).
Murine LPS study
Ten C57Bl6 female mice were given intraperitoneal injections
of a 100 mg of lipopolysaccharide endotoxin (LPS) from E. coli
055:B5 (Sigma-Aldrich, St. Louis, MO) to induce sepsis syndrome
as previously described [28]. Peripheral blood was collected 6h
later from treated and control mice, and RNA was processed as
described in the irradiation studies.
Human Irradiation and Chemotherapy Treatment Studies
With approval from the Duke University Institutional Review
Board (IRB), between 5–12 mL of peripheral blood was collected
from patients prior to and 6 hrs following total body irradiation with
150to200cGyaspartoftheirpre-transplantationconditioning[27].
For additional comparison, peripheral blood was obtained from
healthy volunteers and an additional cohort of patients prior to and
6 hrs following the initiation of alkylator-based chemotherapy alone
(without radiotherapy). All patients and healthy volunteers who
participated in this study provided written informed consent prior to
enrollment, as per the Duke IRB guidelines. PB MNCs and total
RNA were isolated from the blood using the identical methods as
described for collection of murine cells and RNA.
DNA Microarrays
Mouse and human oligonucleotide arrays were printed at the
Duke Microarray Facility using Operon’s Mouse Genome Oligo
sets (version 3.0 and version 4.0) and Operon’s Human Genome
Oligo set (version 3.0 and version 4.0). Data generated from
Operon’s Mouse and Human version 3 was previously described
[27]. Operon’s Mouse Genome Oligo set (version 4.0) (https://
www.operon.com/arrays/oligosets_mouse.php) contains 35,852
oligonucleotide probes representing 25,000 genes and approxi-
mately 38,000 transcripts. Operon’s Human Genome Oligo set
(version 4.0) (https://www.operon.com/arrays/oligosets_human.
php) contains 35,035 oligonucleotide probes, representing approx-
imately 25,100 unique genes and 39,600 transcripts. In order to
compare across versions of the Operon oligo sets, Operon
provided a map that matched the probes from both versions
and only those oligonucleotides that overlapped between versions
3.0 and 4.0 were used in the analysis.
RNA and Microarray Probe Preparation and Hybridization
Briefly, MNCs were pelleted, and total RNA was isolated using
the RNAeasy mini spin column [27]. Total RNA from each
sample (mouse or human) and the universal reference RNA
(Universal Human or Mouse Reference RNA, Stratagene, http://
www.stratagene.com) were amplified and used in probe prepara-
tion as previously described [27]. The sample (mouse or human)
was labeled with Cy5 and the reference (mouse or human) was
labeled with Cy3. The reference RNA allows for the signal for
each gene to be normalized to its own unique factor allowing
comparisons of gene expression across multiple samples. This
serves as a normalization control for two-color microarrays and an
internal standardization for the arrays. Amplification, probe
preparation and hybridization protocols were performed as
previously described [27] and each condition examined had
multiple replicates analyzed (n=3–18 per mouse condition and
n=18–36 per human condition). Detailed protocols are available
on the Duke Microarray Facility web site (http://microarray.
genome.duke.edu/services/spotted-arrays/protocols).
Data Processing and Statistical Analysis
Genespring GX 7.3 (Agilent Technologies) was used to perform
initial data filtering in which spots whose signal intensities below
70 in either the Cy3 or Cy5 channel were removed. For each
analysis, only those samples in that analysis were used in the
filtering process. To compare data from previously published
results [27], we only used those probes that mapped to each other
across the version 3.0 and version 4.0 arrays. To then account for
missing values, PAM software (http://www-stat.stanford.edu/
,tibs/PAM/) was used to impute missing values. k-nearest
neighbor was used where missing values were imputed using a k-
nearest neighbor average in gene space. In the analysis approach
in which all samples were included, lowess normalization of the
data followed by batch effect removal using 2-way mixed model
ANOVA (Partek Incorporated) was performed. Gene expression
profiles of dose response were used in a supervised analysis using
binary regression methodologies as described previously [27].
Prediction analysis of the expression data was performed using
MATLAB software as previously described [27]. When predicting
levels of radiation exposure, gene selection and identification is
based on training the data and finding those genes most highly
correlated to response. Each signature summarizes its constituent
genes as a single expression profile and is here derived as the first
principal component of that set of genes (the factor corresponding
to the largest singular value), as determined by a singular value
decomposition. Given a training set of expression vectors (of values
across metagenes) representing two biological states, a binary
probit regression model is estimated using Bayesian methods.
Bayesian fitting of binary probit regression models to the training
data then permits an assessment of the relevance of the metagene
signatures in within-sample classification, and estimation and
uncertainty assessments for the binary regression weights mapping
metagenes to probabilities of radiation exposure. To internally
validate the predictive capacity of the metagene profiles, we
Radiation Signatures
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previously described [27]. A leave one out cross validation involves
removing one sample from the dataset, using the remaining
samples to develop the model, and then predicting the status of the
held out sample. This is then repeated for each sample in the
dataset. We have utilized this approach as previously described
[27]. A ROC curve analysis was used to define a cut-off for
sensitivity and specificity in the predictive models of radiation.
Genes found to be predictive of radiation dose were characterized
utilizing an in-house program, GATHER (http://meddb01.duhs.
duke.edu/gather/). GATHER quantifies the evidence supporting
the association between a gene group and an annotation using a
Bayes factor [29]. All microarray data files can be found at http://
data.cgt.duke.edu/ChuteRadiation.php and at gene expression
omnibus website (GEO [http://www.ncbi.nlm.nih.gov/geo], ac-
cession number GSE10640).
Results
PB gene expression signatures predict ionizing radiation
exposure in a heterogeneous population
In a previous study, we demonstrated that PB collected from a
single strain and gender of mice, at a single time point, contained
patterns of gene expression that predicted both prior radiation
exposureand distinguisheddifferentlevelsofradiationexposurewith
a high degree of accuracy [27]. In this study, we sought to determine
whether PB gene expression signatures could be identified that
predict radiation exposure status within a population that was
heterogeneous for genotype,gender and timeof sampling. We found
that a clear pattern of gene expression could be identified within this
heterogeneous population of mice that distinguished non-irradiated
animals from those irradiated with 50 cGy, 200 cGy, and 1000 cGy
(Figure 1A). To verify that these patterns did indeed represent genes
reflecting exposure to radiation, we utilized a leave-one-out cross-
validation analysis to assess the ability of the pattern to predict the
relevant samples (Figure 1B). The results demonstrate that the
pattern selected for distinguishing control animals from those
irradiated at various doses has the capacity to predict the status of
the samples. The accuracies of prediction of the non-irradiated
samples, the 50 cGy-, 200 cGy- and 1000 cGy-irradiated samples
were 92%, 78%, 91% and 100%, respectively.
Sex differences impact the accuracy of gene expression
signatures of radiation
We next sought to determine the extent to which variables
within a heterogeneous population can limit the accuracy of PB
gene expression profiling. In order to address the impact of sex
difference, healthy adult male and female C57Bl6 mice were
irradiated with 50 cGy, 200 cGy, and 1000 cGy and PB was
collected at 6 hours post-irradiation, along with PB from non-
irradiated control mice (n=7–10 per group). Patterns of gene
expression could be identified in the PB of both male and female
mice that appeared to distinguish radiation exposure status
(Figure 2A). When the PB signatures from the male C57Bl6 mice
were tested against the female PB samples, the heat map analysis
suggested less distinction between the non-irradiated and irradi-
ated profiles (Figure 2B). Comparable effects were observed when
the female PB signatures were applied against male PB samples. A
leave-one-out cross-validation analysis demonstrated that the male
and female PB signatures of radiation were 100% accurate in
predicting the radiation status of PB samples from mice of the
same sex (Figure 2C). The male PB signatures also were 100%
accurate in predicting the status of the female mice. However, the
female PB signatures were less accurate in distinguishing the non-
irradiated from 50 cGy irradiated male mice, with improved
accuracy in predicting non-irradiated samples from male mice
irradiated with higher doses of radiation (200 cGy and 1000 cGy;
Figure 2C). The basis for the observed differences in predicting the
radiation status of mice across gender differences may be a
function of the distinct sets of genes which are represented in the
predictors of radiation exposure in males and females (Table S1).
Less than 15% of the genes overlapped between the PB metagenes
of males and females at each dose of radiation (Table S2).
Impact of genotype on prediction of radiation status
Since the human population is genetically diverse, we next
examined whether gene expression signatures of radiation
exposure could accurately predict the status of mice across
different genotypes. PB was collected from C57Bl6 and BALB/c
mice at 6 hours following 50 cGy, 200 cGy or 1000 cGy and we
were able to identify patterns of gene expression which appeared
to distinguish the different levels of radiation from the non-
irradiated controls within each strain (Figure 3A). However, when
the PB gene expression signatures from C57Bl6 mice were tested
against BALB/c mice, and vice versa, the gene expression profiles
were less distinct (Figure 3B). We then performed a leave-one-out
cross-validation analysis in which gene expression profiles from
C57Bl6 mice were tested against PB from BALB/c mice and
found that the metagene predictors of radiation from C57Bl6 mice
displayed 100% accuracy in predicting the status of non-irradiated
and irradiated BALB/c mice (Figure 3C). Similarly, application of
the PB metagene profiles of radiation generated in BALB/c mice
demonstrated 100% accuracy in distinguishing non-irradiated and
irradiated C57Bl6 mice. Interestingly, less than 20% of the genes
represented within the PB predictors from C57Bl6 mice and
BALB/c mice overlapped (Table S3, Table S2), but both
predictors were highly accurate in predicting the radiation status
of the different strain of mice. Dda3, a p53-inducible gene, which
participates in suppression of cell growth [30], was represented in
both strains at all radiation doses.
The impact of time on PB gene expression signatures of
irradiation
PB responses to environmental exposures may change over time
as a function of changes in PB cellular composition and cellular
Figure 1. Peripheral blood gene expression profiles distinguish
irradiated mice within a heterogeneous population (A) The left
panel represents a heat map of a 25 gene profile that can predict
radiation status. The figure is sorted by dosage (0 cGy, 50cGy, 200cGy,
and 1000cGy). High expression is depicted as red, and low expression is
depicted as blue. (B) The right panel is a graph of the predicted
capabilities of the irradiation signature across all mice (including C57Bl6
and BALB/c strains, males and females and 3 sampling time points)
versus a control, non irradiated sample. All predicted probabilities for
the controls are listed.
doi:10.1371/journal.pone.0001912.g001
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control, non-irradiated mice versus 50 cGy, 200 cGy, or 1000 cGy irradiated mice within female (top) and male C57Bl6 mice (bottom). (B) Heat map
images illustrating expression pattern of genes found in the female C57Bl6 strain or male C57Bl6 strain predicting the irradiation status of the
opposite sex at dosage 50 cGy, 200 cGy, 1000 cGy. High expression is depicted as red, and low expression is depicted as blue. (C) A leave-one-out
cross-validation analysis of the classification for control (blue) versus 50 cGy (black), 200 cGy (green), and 1000 cGy (red) for the female C57Bl6
(squares) and male C57Bl6 (circles) samples is shown. The control probabilities for each prediction are shown.
doi:10.1371/journal.pone.0001912.g002
Figure 3. Impact of genotype on murine irradiation profiles. (A) Heat map images illustrating expression pattern of genes selected for
classifying control, non-irradiated samples versus 50 cGy, 200 cGy, 1000 cGy irradiated samples between female C57Bl6 strain (top) and female BALB/
c strain (bottom). (B) Heat map images illustrating expression pattern of genes developed in one strain as predicting the other strain (C57Bl6 or BALB/
c). High expression is depicted as red and low expression is depicted as blue. (C) A leave-one-out cross-validation analysis of the classification for
control versus 50 cGy (black), 200 cGy (green), and 1000 cGy (red) for the female BALB/c and female C57Bl6 samples is shown. The control
probabilities for each prediction are shown. BK represents the application of female C57Bl6 metagenes to predict the status of female BALB/c mice,
and BC represents using female BALB/c mice metagenes to predict the status of female C57Bl6 mice.
doi:10.1371/journal.pone.0001912.g003
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the PB of C57Bl6 female mice at 6 hrs, 24 hrs and 7 days post-
irradiation which appeared to distinguish the 3 different levels of
radiation versus non-irradiated mice (Figure 4A). When the PB
metagene profiles of radiation exposure generated from the 6 hr
time point were applied against PB samples from mice at the 24 hr
and 7 day time points post-irradiation, the profiles appeared less
distinct (Figure 4B). A leave-one-out cross-validation analysis
demonstrated that the PB metagene profiles from each time point
predicted each dose of radiation with 100% accuracy (Figure 4C).
Next, a leave-one-out cross-validation analysis was performed
using the metagene profiles from the 6 hr time point against each
of the PB samples from mice at 24 hr and 7 day time points and
the 6 hr metagene profiles demonstrated 100% accuracy in
predicting the radiation status of the 24 hr and 7 day time point
samples (Figure 4C). Of note, the 7 day time point following 1000
cGy exposure could not be analyzed since we were unable to
collect sufficient RNA from these PB samples to allow gene array
hybridization to be performed. Although we found that time did
not impact the accuracy of PB gene expression profiles in
predicting radiation status, the lists of genes which comprised
these PB signatures changed significantly over 7 days (Table S4).
No genes were found in common between the 6 hr predictors and
the 24 hr or 7 day PB signatures of radiation in 50 cGy-, 200 cGy-
, or 1000 cGy-treated mice (Table S2). A single gene, Galectin 1
(Lgals1), a carbohydrate binding protein that is involved in the
induction of cell death [31], was found in common between the
24 hr and 7 day predictors of 50 cGy.
Specificity of PB signatures
In addition to inter-individual variations [12], human popula-
tions are heterogeneous with respect to health status and medical
conditions. Therefore, it is critical to determine whether PB gene
expression profiles of radiation response are specific to radiation
exposure itself or whether these signatures are potentially
confounded by other genotoxic stresses. We chose to compare
the PB gene expression response to ionizing radiation exposure
with that of gram-negative bacterial sepsis, since this syndrome can
be expected to induce similar multiorgan toxicity as is observed
following radiation injury [15–17,32]. A pattern of gene expression
could be identified which effectively distinguished female C57Bl6
mice treated with Escherichia coli-derived lipopolysaccharide
(LPS), experiencing sepsis syndrome, from untreated female
C57Bl6 mice (Figure 5A). Applying a leave-one-out cross-
validation analysis, we found that the PB signature for 50 cGy
irradiation in C57Bl6 mice correctly predicted the status of all
LPS-treated C57Bl6 mice as non-irradiated, suggesting robust
specificity of the signature for low level (50 cGy) irradiation and
sepsis syndrome (Figure 5B). The PB signatures for 200 cGy and
1000 cGy also correctly predicted the LPS-treated mice as non-
irradiated, although these probabilities were less robust than the
application of the 50 cGy signature (Figure 5B). The PB signature
of LPS-treatment also correctly predicted the status of all
irradiated mice as ‘‘non-LPS treated’’ (Figure 5B, right). These
data indicate that the PB gene expression profiles of radiation
response and bacterial sepsis are quite specific and able to
distinguish one condition from the other with a high level of
Figure 4. Impact of time on murine irradiation profiles. (A) Heat map images illustrating expression pattern of genes selected for classifying
control, non-irradiated samples versus 50 cGy, 200 cGy, 1000 cGy irradiated samples at time points 6hr, 24hr, and 7days. (B) Heat map images
illustrating expression pattern of genes found in the 6hr time point as applied to the dosages 50 cGy, 200 cGy, 1000 cGy at 24 hr and 7 day time
points. High expression is depicted as red, and low expression is depicted as blue. (C) A leave-one-out cross-validation analysis of the classification for
control (blue) versus 50 cGy (black), 200 cGy (green), and 1000 cGy (red) for the time points 6 hr (circles), 24 hr (squares), and 7 days (triangles) is
shown. The control probabilities for each prediction are shown.
doi:10.1371/journal.pone.0001912.g004
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comprised the PB signature of LPS-sepsis and the PB signatures of
radiation exposure in C57Bl6 mice (Table S5).
PB signatures of radiation and chemotherapy are specific
in humans
In order to extend the analysis of PB signature specificity to
humans, we collected PB from a population of healthy individuals
(n=18), patients who had undergone total body irradiation as
conditioning prior to hematopoietic stem cell transplantation
(n=47) and patients who had undergone alkylator-based chemo-
therapy conditioning alone (n=41). RNA of sufficient quality was
available from 18 healthy donor samples, 36 pre-irradiated
patients, 34 post-irradiated patients, 36 pre-chemotherapy treat-
ment patients and 32 post-chemotherapy patients (Table S6). A
supervised binary regression analysis identified a metagene profile
of 25 genes that distinguished the healthy individuals and the non-
irradiated patients from the irradiated patients (Figure 6A). A
leave-one-out cross validation analysis demonstrated that this PB
predictor of human radiation response was 100% accurate in
predicting the healthy individuals and the non-irradiated patients
and 91% accurate at predicting the irradiated patients (Figure 6A).
In order to test the specificity of this PB signature of human
radiation response, we next tested its accuracy in predicting the
status of patients who had undergone chemotherapy treatment
alone. This signature correctly predicted 89% of the non-
irradiated, pre-chemotherapy patients as non-irradiated and
75% of the chemotherapy-treated patients as non-irradiated
(Figure 6A). Interestingly, 2 of the post-chemotherapy patients
had a prior history of total lymphoid irradiation and both of these
were mispredicted as ‘‘irradiated’’, suggesting perhaps that a
durable molecular response to radiation was evident in these
patients. Considering the entire population, the overall accuracy of
the PB predictor of radiation was 90%. Within the chemotherapy-
treated patients, a PB signature could be identified that appeared to
distinguish untreated patients from chemotherapy-treated patients
(Figure 6B). A leave-one-out cross-validation analysis demonstrated
that this PB signature of chemotherapy treatment was 81% accurate
at distinguishing the untreated patients and 78% accurate at
predicting the chemotherapy-treated patients (Figure 6B). Further-
more, the chemotherapy metagene profile demonstrated 100%
accuracy in predicting the status of healthy individuals, 92%
accuracy in predicting the non-irradiated patients, and 62%
accuracy in predicting the PB samples from irradiated patients as
not having received chemotherapy (Figure 6B). The overallaccuracy
of the PB predictor of chemotherapy-treatment was 81%.
Interestingly, no overlapping genes were identified between the PB
signature of radiation and the PB signature of chemotherapy
treatment(Tables S7and S8). It isalso worth noting thatall 12 of the
post-irradiation patients whose status was mispredicted by the PB
chemotherapy signature had received prior chemotherapy in the
treatment of their underlying disease.
Discussion
Numerous studies now highlight the power of gene expression
profiling to characterize the biological phenotype of complex
diseases. We and others have shown the potential clinical utility of
gene expression profiles in cancer research, in which the identifica-
tion of patterns of gene expression within tumors has led to the
characterization of tumor subtypes, prognostic categories and
prediction of therapeutic response [33–37]. Beyond analysis of
tumortissues,ithasalsobeensuggestedthatgeneexpressionprofiling
of the peripheral blood can provide indication of infections, cancer,
heart disease, allograft rejection, environmental exposures and as a
means of biological threat detection [3–11,38,39]. While the concept
of PB cells as sentinels of disease is not new, it remains unclear
whether PB gene expression profiles that have been associated with
various conditions are specific for those diseases or rather reflect a
common molecular response to a variety of genotoxic stresses. Given
the dynamic nature of the cellular composition of PB blood [12] and
the complexity of cellular responses over time [12], the durability of
PB signatures over time is also uncertain and could affect the
diagnostic utility of this approach for public health screening.
We sought to address the capacity for PB gene expression
profiles to distinguish an environmental exposure, in this case
ionizing radiation, versus other medical conditions and to examine
the impact of time, gender and genotype on the accuracy of these
profiles. We found that PB gene expression signatures can be
identified which accurately predict irradiated from non-irradiated
mice and distinguish different levels of radiation exposure, all
within a heterogeneous population with respect to gender,
genotype and time from exposure. These results suggest the
potential for PB gene expression profiling to be applied successfully
in the screening for an environmental exposure. Previous studies
have indicated that inter-individual variation in gene expression
occurs within healthy individuals [12] and may therefore limit the
accuracy of PB gene expression profiling to detect diseases or
exposures. Our results demonstrate that the environmental
exposure tested here, ionizing radiation, induced a pronounced
and characteristic alteration in PB gene expression such that a PB
expression profile was highly predictive of radiation status in a
population with variable gender, genotype and time of analysis.
From a practical standpoint, these data suggest the potential utility
of this approach for biodosimetric screening of a heterogeneous
human population in the event of a purposeful or accidental
radiological or nuclear event [15–17].
Figure 5. Peripheral blood profiles of irradiation and LPS-
treatment are highly specific. (A) Heat maps representing unique
metagene profiles are shown which were utilized to distinguish 3
different levels of irradiation (left) and to distinguish LPS-treatment
(right) in C57Bl6 mice. (B) The graph at left represents the predictive
capabilities of the PB irradiation signatures in the female C57Bl6 mice in
predicting dosage profiles at 50 cGy (black), 200 cGy (green), and 1000
cGy (red); the middle graph represents the predictive capabilities of the
irradiation signatures when validated against the LPS-treated samples
(squares); at right, the LPS signature was validated against the C57Bl6
irradiated mice and the predicted probabilities for 50 cGy (black), 200
cGy (green), and 1000 cGy (red) are shown.
doi:10.1371/journal.pone.0001912.g005
Radiation Signatures
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of this approach, particularly in distinguishing mice exposed to
lower dose irradiation from non-irradiated controls. These results
imply that aspects of the PB response to ionizing radiation are
specified by sex-associated genes. Whitney et al. [12] previously
showed that sex differences were associated with variation in PB
autosomal gene expression in healthy individuals. Our study
suggests that sex differences may contribute to characteristically
distinct PB molecular responses to environmental stress (radiation)
and the accuracy of PB gene expression profiling for medical
screening can be affected by sex. These sex-related differences in
PB response to ionizing radiation are perhaps illustrated by the
fact that only 2 genes overlapped between the male and female PB
signatures of 50 cGy (Ccng1 and Dda3).
Interestingly, differences in genotype did not significantly
impact the accuracy of the PB gene expression signatures to
distinguish radiation response such that PB signatures from
C57Bl6 mice displayed 100% accuracy in predicting the status
of BALB/c mice and vice versa. This observation demonstrates
that, while genotype differences can account for some variation in
PB gene expression [12], the alterations in PB gene expression
induced by 3 different levels of radiation exposure are such that PB
expression profiling is highly accurate in distinguishing all
irradiated mice across different genotypes. Very few genes were
found in common between the 2 strains of mice at each level of
radiation exposure, indicating that diverse sets of genes contribute
to the PB response to radiation and that unique sets of genes can
be identified which are predictive of radiation response.
The time of PB collection following radiation exposure had no
significant impact on the accuracy of PB signatures to predict
radiation status or distinguish different levels of exposure. First, the
accuracy of PB signatures to predict radiation status and
distinguish different levels of radiation exposure did not decay
over time. Second, when we applied a PB signature from a single
time point (6 hrs) against PB samples collected from mice at other
time points (24 hr and 7 days), the accuracy of the prediction
remained 100% in all cases. Therefore, time as a single variable
did not lessen the accuracy of this approach to distinguish
irradiated from non-irradiated animals. However, the content of
the genes which comprised the PB signatures changed significantly
as a function of time and ,20% of the genes overlapped between
the PB signatures of radiation at 6 hr, 24 hr, and 7 days. Taken
together, these data indicate that PB predictors of radiation
response do change over time, but PB signatures can continuously
Figure 6. PB metagene profiles of human radiation exposure and chemotherapy treatment are accurate and specific relative to
each other. (A) The heat map on the left depicts the expression profiles of genes (rows) selected to discriminate the human samples (columns); high
expression is depicted as red, and low expression is depicted as blue. A leave-one-out cross-validation assay (at right) demonstrated that the PB
metagene of radiation was capable of distinguishing healthy donors (black), non-irradiated patients (gray), irradiated patients (red), pre-
chemotherapy treatment patients (green), and post-chemotherapy patients (blue). A ROC curve analysis was used to define a cut-off for sensitivity
and specificity of the predictive model of radiation. The dotted line represents this threshold of sensitivity and specificity. (B) The heatmap on the left
depicts an expression profile of chemotherapy treatment that distinguishes chemotherapy-treated versus untreated patients. A leave-one-out cross-
validation assay demonstrated that this PB metagene of chemotherapy treatment could accurately distinguish pre-chemotherapy patients (green),
chemotherapy-treated patients (blue), healthy individuals (black), pre-irradiated patients (gray) and irradiated patients (red).
doi:10.1371/journal.pone.0001912.g006
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radiation status and distinguishing different levels of radiation
exposure. From a practical perspective, these results suggest that
the application of a single reference set of ‘‘radiation response’’
genes would be unlikely to provide the most sensitive screen for
radiation exposure over time. Conversely, reference lists of PB
genes that are specific for different time points could be applied in
the screening for radiation exposure provided that the time of
exposure was known.
A critical question to be addressed in the development of PB
gene expression profiling to detect medical conditions or exposures
is the specificity of PB gene expression changes in response to
genotoxic stresses. The PB signatures of 3 different doses of
radiation displayed 100% accuracy in identifying septic animals as
non-irradiated and the PB signature of sepsis was also 100%
accurate in identifying irradiated mice as non-septic. These results
demonstrate specificity in the PB responses to ionizing radiation
and sepsis. These data also provide in vivo validation of a prior
report by Boldrick et al. [40] in which human PB mononuclear
cells were found to have a stereotypic response to LPS exposure in
vitro and specific alterations in gene expression were observed in
response to different strains of bacteria [40]. Ramilo et al. also
recently reported that distinct patterns of PB gene expression can
be identified among patients with different bacterial infections
[11]. We found no genes in common between the PB signatures of
radiation exposure and the PB signature of gram negative sepsis.
Taken together, our results demonstrate that the in vivo PB
molecular responses to ionizing radiation and bacterial sepsis are
quite distinct and can be utilized to distinguish one condition from
the other with a high level of accuracy.
Our analyses of expression signatures in human patients
demonstrated that it is possible to utilize PB gene expression
profiles to distinguish individuals who have been exposed to an
environmental hazard, ionizing radiation, within a heterogeneous
human population with a high level of accuracy. It will be
important to further test the accuracy of this PB predictor of
human radiation exposure in a human population exposed to
lower dose irradiation (e.g. 0.1–1 cGy), as might be expected via
occupational exposures (e.g. radiology technicians, nuclear power
plant workers)[41–43]. A potential pitfall in the clinical application
of PB gene expression profiling would be that variations in PB
gene expression in people would be such that it might be difficult
to distinguish the effects of a given exposure or medical condition
from expected background alterations in gene expression [12].
However, Whitney et al. [12] showed that the alterations in PB
gene expression observed in patients with lymphoma or bacterial
infection was significantly greater than the relatively narrow
variation observed in healthy individuals [12]. Our study confirms
that PB gene expression profiles can be successfully applied to
detect a specific exposure in a heterogeneous human population
and that inter-individual differences in PB gene expression do not
significantly confound the utility of this approach.
We further showed that unique PB gene expression profiles can
be identified which distinguish chemotherapy-treated patients
versus patients who had not received chemotherapy with an
overall accuracy of 81% and 78%, respectively. Similar to the PB
signature of radiation, the PB signature of chemotherapy
demonstrated accuracy and specificity in distinguishing healthy
individuals and pre-irradiated patients (100% and 92% accuracy,
respectively). However, the accuracy of the PB signature of
chemotherapy was more limited when tested against patients who
received radiation conditioning (62%). This observation provides
the basis for further investigation as to which families of genes may
be represented in both the PB molecular response to radiation and
chemotherapy. However, since all 12 of the post-irradiation
patients whose status was mispredicted by the PB chemotherapy
signature had received combination chemotherapy within the
prior year, the true specificity of this PB signature of chemotherapy
cannot be addressed via this comparison. We are currently
enrolling additional patients to this study who have not undergone
prior chemotherapy to further test the specificity of a PB metagene
of chemotherapy treatment.
Peripheral blood is a readily accessible source of tissue which
has the potential to provide a window to the presence of disease or
exposures. Early studies applying PB gene expression analysis have
demonstrated that this approach is sensitive for the detection of
patterns of gene expression in association with a variety of medical
conditions [3–12,27]. It remains to be determined whether PB
gene expression profiles can be successfully applied in medical
practice or public health screening for the early detection of
specific diseases or environmental exposures. Our results demon-
strate that PB gene expression profiles can be identified in mice
and humans which are specific, accurate over time, and not
confounded by inter-individual differences.
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